Home » Stocks » XOMA

XOMA Corporation (XOMA)

Stock Price: $33.40 USD 0.89 (2.74%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $33.50 +0.10 (0.30%) Jul 23, 4:01 PM
Market Cap 376.40M
Revenue (ttm) 28.96M
Net Income (ttm) 10.15M
Shares Out 11.24M
EPS (ttm) 0.49
PE Ratio 67.61
Forward PE 196.08
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $33.40
Previous Close $32.51
Change ($) 0.89
Change (%) 2.74%
Day's Open 32.51
Day's Range 32.31 - 33.49
Day's Volume 5,037
52-Week Range 15.48 - 46.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ: CMPI) vidutolimod (CMP-001), for $7.0 million upfront plus ...

1 week ago - Benzinga

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules

1 week ago - GlobeNewsWire

EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals'...

1 week ago - GlobeNewsWire

Stocks were mostly higher in midday Tuesday trading, after both the S&P 500 and the Nasdaq closed at record highs on Monday.

Other stocks mentioned: TSLA, TXT, NTR, OAS, STEM, TTM, TWO
3 weeks ago - 24/7 Wall Street

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to hold...

1 month ago - GlobeNewsWire

EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annua...

2 months ago - GlobeNewsWire

Xoma (XOMA) delivered earnings and revenue surprises of -366.67% and -69.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

XOMA's portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash.  The April 2021 $40 million Series...

2 months ago - GlobeNewsWire

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen)...

2 months ago - GlobeNewsWire

EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of t...

3 months ago - GlobeNewsWire

Raised aggregate gross proceeds of $40 million

3 months ago - GlobeNewsWire

Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock

3 months ago - GlobeNewsWire

EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of depositary...

3 months ago - GlobeNewsWire

EMERYVILLE, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors approved a dividend of $0.71875 per share to holde...

4 months ago - GlobeNewsWire

Xoma (XOMA) delivered earnings and revenue surprises of 2.33% and 126.07%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Recognized revenue of $29.4 million  Six assets in the Company's milestone and royalty portfolio advanced to Phase 2 clinical development  Completed $24.6 million Series A Perpetual Preferred Stock offe...

4 months ago - GlobeNewsWire

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

EMERYVILLE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:

5 months ago - GlobeNewsWire

XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty aggregato...

6 months ago - Seeking Alpha

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

6 months ago - GlobeNewsWire

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered public off...

7 months ago - GlobeNewsWire

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 880,000 shar...

7 months ago - GlobeNewsWire

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of i...

7 months ago - GlobeNewsWire

XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Co...

8 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ: AGE...

8 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in XOMA.

8 months ago - Zacks Investment Research

Xoma (XOMA) delivered earnings and revenue surprises of 52.38% and -75.78%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 mi...

8 months ago - GlobeNewsWire

EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc....

8 months ago - GlobeNewsWire

EMERYVILLE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development...

8 months ago - GlobeNewsWire

EMERYVILLE, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned $1.9 million in payments from two partners. The Company earn...

9 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

10 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in XOMA.

11 months ago - Zacks Investment Research

Xoma (XOMA) delivered earnings and revenue surprises of 13.16% and -74.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts Partners continue to advance clinical assets within the XOMA miles...

11 months ago - GlobeNewsWire

Live video feed will be available on XOMA’s website Live video feed will be available on XOMA’s website

11 months ago - GlobeNewsWire

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

EMERYVILLE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, Inc., has jo...

1 year ago - GlobeNewsWire

EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the annual rec...

1 year ago - GlobeNewsWire

XOMA (XOMA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody

1 year ago - GlobeNewsWire

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in XOMA.

1 year ago - Zacks Investment Research

Raises $22 million from existing stockholders Raises $22 million from existing stockholders

1 year ago - GlobeNewsWire

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Other stocks mentioned: CHRS, MGTX, MRNA, QURE
1 year ago - Zacks Investment Research

Why you should keep an eye on these potential outperformers this month.

Other stocks mentioned: CASY, CTAS, XOM
1 year ago - The Motley Fool

EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for w...

1 year ago - GlobeNewsWire

About XOMA

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
XOMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is 52.33, which is an increase of 56.68% from the latest price.

Price Target
$52.33
(56.68% upside)
Analyst Consensus: Buy